Skip to main content

Chondrosarcoma clinical trials at UC Cancer

2 research studies open to eligible people

Showing trials for
  • Study of INBRX-109 in Conventional Chondrosarcoma

    open to eligible people ages 18 years and up

    Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

    at UCSF

  • Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

    open to eligible people ages 18 years and up

    This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 130 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.

    at UCSF

Last updated: